Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.17 USD | -5.65% | -14.90% | -31.76% |
Jun. 04 | Lumos Pharma, Inc. Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024 | CI |
May. 15 | Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.76% | 18.67M | |
+34.75% | 52.85B | |
-8.19% | 38.87B | |
+34.86% | 38.24B | |
-11.12% | 26.79B | |
+12.27% | 26.16B | |
-19.30% | 19.9B | |
+38.97% | 13.18B | |
+31.42% | 12.24B | |
-3.53% | 11.79B |
- Stock Market
- Equities
- LUMO Stock
- News Lumos Pharma, Inc.
- Oppenheimer Adjusts Lumos Pharma Price Target to $17 From $18, Maintains Outperform Rating